Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11255805 | 0.86 | LMNA (0.58) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL2853073 | 0.85 | LMNA (0.73) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL2853072 | 0.85 | LMNA (0.73) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL20560143 | 0.84 | LMNA (0.67) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL584346 | 0.84 | ALDH1A1 (0.73) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| Nitric Acid SCHEMBL3859433 | 0.83 | LMNA (0.58) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL27761089 | 0.82 | MAPK1 (0.54) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6717028 | 0.82 | LMNA (0.64) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL5881545 | 0.81 | LMNA (0.63) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL9843646 | 0.81 | LMNA (0.66) | MEN1KMT2ALMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101875961-A | Be used to prevent and treat associated conditions and as the diaryl and the aryl heteroaryl urea derivatives of 5-HT2A serotonin receptor modulator | ARENA PHARM INC | 2010-11-03 | — | — | CN | disclosed |
| CN-101871931-A | Be used to prevent and treat associated conditions and as the diaryl and the aryl heteroaryl urea derivatives of 5-HT2A serotonin receptor modulator | ARENA PHARM INC | 2010-10-27 | — | — | CN | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| CN-1826322-A | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT 2A serotonin receptor for the prevention and treatment of related disorders | ARENA PHARM INC (US) | 2006-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MEN1 647/4885KMT2A 792/4885LMNA 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.